Q-omics provides the consensus-scored SERPINB5 profile across patient tissues and cancer cell-line models. SERPINB5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SERPINB5 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SERPINB5 protein abundance shows 21,318 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, COAD, and HNSC as cancer lineages where SERPINB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINB5 survival associations across molecular data types. SERPINB5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINB5 RNA expression–survival associations across cancer types. High SERPINB5 expression shows unfavorable associations in MESO, KIRC, LUAD, PAAD and KICH, but favorable associations in OV. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SERPINB5 RNA expression.
This table summarizes SERPINB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SERPINB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINB5 shows lower tumor expression in BRCA and higher tumor expression in COAD, LUSC, LUAD, STAD and HNSC. The COAD box plot shows higher SERPINB5 RNA expression in tumor versus normal tissue (log2 FC = +3.254, t-test p < 0.001).
This table shows molecular features associated with SERPINB5 in patient tissues and cancer cell lines. In patient samples, SERPINB5 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
